Virtual press conference in the run -up to the Pharmig Academy Rare Diseases Dialogs

Gen therapies open up new ones promising options for the treatment of rare diseases. Initial experiences from practice show her potentialto significantly improve the lives of many affected people. At the same time it is important that Expectations realistic to keep.

How do gene therapies work and what makes it so special? How can the potential of genetic therapies to treat less frequent diseases be exhausted? What contribution can systematic experiences of those affected make?

These and many other questions are the focus of the 17th Rare Diseases dialogue and the virtual press conference. The following experts are available in advance of media representatives:

• Martin MotherPhD: Molekularbiologe, Science Buster
• Dr. Sylvia nanz: Medical Director, Pfizer Corporation Austria | Co-Chair, PHARMIG Standing Committee Rare Diseases
• Present. Priv.-Doz. Dr. med. univ. Markus Ritter: Head of the special ambulance for hereditary retinal diseases – ophthalmogenetics, Medical University of Vienna (MUW)
• Martina Rötzer: Chairwoman, SMA patient representative Austria
• Univ.-Prof. Mag. Dr. Tanja StammPhD, MSc, MBA: Head of the Institute for Outcomes Research at the MedUni Wien and of the Ludwig Boltzmann Institute for Arthritis and Rehabilitation

Moderation: Peter RichterPharmig
Datum: 14. Mai 2025, 10:00 UHR, via Microsoft teams

Please register with Peter Richter at peter.richter@pharmig.at. You will receive the link to the event after registration.

The Rare Diseases Dialog takes place on May 14, 2025 at 4:00 p.m. in Urania Vienna. Participation is possible both on site and virtually.

About the Pharmig Academy: The Pharmig Academy is the training and further education institute of the Pharmig, the Association of the Pharmaceutical Industry of Austria. It offers seminars, courses and training sessions on all topics of healthcare. The offer is based on current developments and is aimed at everyone who is interested in the health sector or are active in it. The format of the Rare Diseases Dialog offers all affected, interested and relevant actors an open discussion platform on current topics in the field of rare diseases.

About the pharmig: Pharmig is the voluntary, party -political independent advocacy of the pharmaceutical industry in Austria. The approximately 120 member companies (as of May 2025) with around 18,000 employees cover the domestic pharmaceutical market for a good 95 percent. Pharmig and their member companies stand for the best possible security of supply with medicinal products in healthcare and ensure social and medical progress through quality and innovation.

Virtual press conference – Pharmig Academy Rare Diseases Dialogue

Please register with Peter Richter at peter.richter@pharmig.at.

Datum: 14.05.2025, 10:00 a.m.

Art: Press and

Ort: Microsoft Teams